Extended Data Fig. 10: Efficacy of H9T in adoptive cell immunotherapy. | Nature

Extended Data Fig. 10: Efficacy of H9T in adoptive cell immunotherapy.

From: An engineered IL-2 partial agonist promotes CD8+ T cell stemness

Extended Data Fig. 10

a, Tumour growth after transfer of pmel-1 cells that expanded with IL-2, H9 or H9T for 8 days into B16 melanoma-bearing mice, with PBS as a control. n = 14 for H9 group and n = 15 mice for all other groups; data are from three independent repeats. b, Blood cells from mice cured of B16 melanoma tumour after adoptive transfer of H9T-expanded CD8+ pmel-1 cells were stained for CD8 and CD90.1. Data are from two independent experiments. c, d, IL-2- or H9T-expanded CD8+ pmel-1 cells were transferred into B16 melanoma-bearing mice, with PBS as a control. Mice were irradiated one day before cell transfer but not injected i.p. with IL-2 after cell transfer (no IP) or not irradiated but injected with 180,000 IU IL-2 i.p. daily for 3 days beginning on the day of transfer (no IR). Data are mean ± SEM, n = 5 mice. Data are from two independent repeats. eg, TIM-3 and PD1 profiling of pmel-1 cells in tumour and draining lymph nodes 7 days after adoptive transfer. Data are mean ± SEM, n = 5 mice, one-way ANOVA test with Dunnett’s correction. Gating strategy is shown (g). Data are from three independent repeats. h, B16 tumour size 8 days after pmel-1 CD8+ T cells infusion. Data are mean ± SEM, n = 5 mice. Data are from three independent repeats. i, j, Phenotype of pmel-1 cells in tumour and draining lymph nodes 5 or 10 days after adoptive transfer. Data are from two independent experiments. km, Seven days after adoptive transfer, CD8+CD90.1+ cells was sorted from draining lymph nodes and analysed by RNA-seq. Selected gene expression (k, l) and GSEA analysis of memory versus exhausted cells (m) with Kolmogorov–Smirnov test are shown. Data are from two independent repeats

Source data.

Back to article page